Ultragenyx Pharmaceutical (RARE) Accumulated Depreciation & Amortization (2016 - 2025)
Ultragenyx Pharmaceutical (RARE) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $112.0 million as the latest value for Q4 2024.
- On a quarterly basis, Accumulated Depreciation & Amortization rose 34.29% to $112.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was $112.0 million, a 34.29% increase, with the full-year FY2024 number at $112.0 million, up 34.29% from a year prior.
- Accumulated Depreciation & Amortization was $112.0 million for Q4 2024 at Ultragenyx Pharmaceutical, up from $83.4 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $112.0 million in Q4 2024 to a low of $37.4 million in Q4 2020.
- A 5-year average of $69.2 million and a median of $63.4 million in 2022 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: soared 43.88% in 2020, then increased 26.67% in 2022.
- Ultragenyx Pharmaceutical's Accumulated Depreciation & Amortization stood at $37.4 million in 2020, then skyrocketed by 33.82% to $50.0 million in 2021, then grew by 26.67% to $63.4 million in 2022, then surged by 31.59% to $83.4 million in 2023, then soared by 34.29% to $112.0 million in 2024.
- Per Business Quant, the three most recent readings for RARE's Accumulated Depreciation & Amortization are $112.0 million (Q4 2024), $83.4 million (Q4 2023), and $63.4 million (Q4 2022).